Mangione Drops Psychiatric Defense in CEO Murder Trial

A New York City judge overseeing the murder trial of Luigi Mangione, accused of killing UnitedHealthcare CEO Brian Thompson, has announced that Mangione will no longer pursue a “psychiatric defense.” This development comes as Mangione’s lawyers indicated he experienced “extreme mental turmoil” during the alleged crime in December 2024. If this defense had been successful, it might have led to psychiatric treatment rather than imprisonment.

This sudden retraction, detailed in recent court filings, occurred just two weeks after closed-door discussions focused on defense strategies, raising eyebrows among media outlets pushing for public access to those records.

In a ruling issued on the same day, Judge Gregory Caro affirmed that previous orders sealing certain records and documents would stay in place following Mangione’s withdrawal from the psychiatric defense. This shift contrasts sharply with earlier discussions that had considered a defense based on an “extreme mental disorder,” which, under New York law, could have resulted in a manslaughter conviction rather than murder.

The implications of this retraction raise several questions, particularly about what evidence was gathered in those private sessions.

Court officials had earlier conveyed that for this psychiatric defense to succeed, evidence would need to convince the jury that Mangione acted out of intense emotional distress when he allegedly shot Thompson outside a Manhattan business conference. Prosecutors, on the other hand, contend that Mangione meticulously planned the murder for months, even documenting his thoughts in a diary and traveling extensively before executing the ambush.

As it stands, Mangione, 28, who has consistently proclaimed his innocence, faces both state and federal charges in this high-profile case. His murder trial is set to commence in September, with the federal proceedings anticipated to follow next year.